Revvity (RVTY) investor relations material

Business performance and growth drivers

• Diagnostics and life sciences segments both contributed to a strong start to the year, with reproductive health and immunodiagnostics showing robust growth, especially outside China.

• Life sciences reagents business saw low single-digit growth, with signs of recovery in academia and research across geographies.

• Reproductive health outperformed long-range plan (LRP) expectations, driven by geographic and menu expansion, despite global birth rate pressures.

• Immunodiagnostics outside China grew mid-single digits, with U.S. and emerging markets showing strong potential, though latent TB testing remains a drag.

• Life sciences growth benefited modestly from extra selling days, with underlying improvement in end markets and academic funding beginning to flow through.

Strategic portfolio actions and capital deployment

• Announced divestiture of China immunodiagnostics business, expected to close by end of 2027, removing a drag on growth and cash flow.

• Proceeds from divestiture will primarily support share buybacks and selective tuck-in acquisitions to address portfolio gaps.

• High confidence in management-led buyer group for the divestiture, with a definitive agreement anticipated soon.

• Capital deployment prioritizes share repurchases, with ongoing openness to strategic M&A and plans to pay off outstanding bond in the second half of the year.

Innovation, software, and AI integration

• Signals software business launched major new products: BioDesign (large molecule features), Xynthetica (ecosystem partnership), and LabGistics (AI-integrated workflow).

• Early customer feedback on BioDesign is positive, with traction expected as contracts renew.

• ACD/Labs acquisition added synergies and talent, with future tuck-in acquisitions considered based on strategic fit and unmet needs.

• Signals platform is deeply embedded in pharma/biotech R&D, with AI and automation seen as productivity enhancers rather than threats.